These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30336706)

  • 1. Targeting adenosine A
    Congreve M; Brown GA; Borodovsky A; Lamb ML
    Expert Opin Drug Discov; 2018 Nov; 13(11):997-1003. PubMed ID: 30336706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting A3 and A2A adenosine receptors in the fight against cancer.
    Merighi S; Battistello E; Giacomelli L; Varani K; Vincenzi F; Borea PA; Gessi S
    Expert Opin Ther Targets; 2019 Aug; 23(8):669-678. PubMed ID: 31189400
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel approaches for targeting the adenosine A2A receptor.
    Yuan G; Gedeon NG; Jankins TC; Jones GB
    Expert Opin Drug Discov; 2015 Jan; 10(1):63-80. PubMed ID: 25311639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A
    Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
    J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blocking Adenosine/A2AR Pathway for Cancer Therapy].
    Liu J; Shi Y; Liu X; Zhang D; Bai Y; Xu Y; Wang M
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):460-467. PubMed ID: 35899442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine A
    Yu F; Zhu C; Xie Q; Wang Y
    J Med Chem; 2020 Nov; 63(21):12196-12212. PubMed ID: 32667814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
    Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
    Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor.
    Eini H; Frishman V; Yulzari R; Kachko L; Lewis EC; Chaimovitz C; Douvdevani A
    Biochem Pharmacol; 2015 Nov; 98(1):110-8. PubMed ID: 26296573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of the adenosine A
    Sun B; Bachhawat P; Chu ML; Wood M; Ceska T; Sands ZA; Mercier J; Lebon F; Kobilka TS; Kobilka BK
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2066-2071. PubMed ID: 28167788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer.
    Ferré S; Bonaventura J; Tomasi D; Navarro G; Moreno E; Cortés A; Lluís C; Casadó V; Volkow ND
    Neuropharmacology; 2016 May; 104():154-60. PubMed ID: 26051403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.
    Hatfield SM; Sitkovsky M
    Curr Opin Pharmacol; 2016 Aug; 29():90-6. PubMed ID: 27429212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adenosine A
    Franco R; Lillo A; Navarro G; Reyes-Resina I
    Expert Opin Ther Targets; 2022 Sep; 26(9):791-800. PubMed ID: 36300278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer.
    Bonaventura J; Navarro G; Casadó-Anguera V; Azdad K; Rea W; Moreno E; Brugarolas M; Mallol J; Canela EI; Lluís C; Cortés A; Volkow ND; Schiffmann SN; Ferré S; Casadó V
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3609-18. PubMed ID: 26100888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine A2A receptor as a drug discovery target.
    de Lera Ruiz M; Lim YH; Zheng J
    J Med Chem; 2014 May; 57(9):3623-50. PubMed ID: 24164628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.
    Mittal D; Young A; Stannard K; Yong M; Teng MW; Allard B; Stagg J; Smyth MJ
    Cancer Res; 2014 Jul; 74(14):3652-8. PubMed ID: 24986517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of (4E)-4-(4-substitutedbenzylideneamino)-3-substituted-2,3-dihydro-2-thioxothiazole-5-carbonitrile as novel A2A receptor antagonists.
    Mishra CB; Sharma D; Prakash A; Kumari N; Kumar N; Luthra PM
    Bioorg Med Chem; 2013 Oct; 21(19):6077-83. PubMed ID: 23953686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Combination Strategies for the A
    Voronova V; Peskov K; Kosinsky Y; Helmlinger G; Chu L; Borodovsky A; Woessner R; Sachsenmeier K; Shao W; Kumar R; Pouliot G; Merchant M; Kimko H; Mugundu G
    Front Immunol; 2021; 12():617316. PubMed ID: 33737925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A
    Renk DR; Skraban M; Bier D; Schulze A; Wabbals E; Wedekind F; Neumaier F; Neumaier B; Holschbach M
    Eur J Med Chem; 2021 Mar; 214():113214. PubMed ID: 33548636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
    Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA
    Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A
    Yan W; Ling L; Wu Y; Yang K; Liu R; Zhang J; Zhao S; Zhong G; Zhao S; Jiang H; Xie C; Cheng J
    J Med Chem; 2021 Nov; 64(22):16573-16597. PubMed ID: 34783558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.